Research Triangle Park, NC – TruTechnologies, the leading provider of real-time clinical trial oversight, today announced its relocation to a new 25,000-square-foot headquarters at Park Point in Research Triangle Park (RTP). The move comes just over a year after the company’s previous expansion and reflects TruTechnologies’ rapid growth and commitment to scaling its operations to meet expanding client demand.

The new space at Park Point – a revitalized 100-acre campus offering a modern, amenity-rich environment for life-science and technology firms – provides the infrastructure, flexibility, and community access needed for the company’s next phase of growth. Named Top Redevelopment Project in the 2022 Triangle Business Journal SPACE Awards, Park Point features indoor and outdoor gathering spaces, fitness and wellness amenities, walking trails, and café services designed to foster collaboration and innovation.

“Outgrowing our space in just a year speaks volumes about the momentum we’re seeing across the clinical trial ecosystem,” said Scott Ogle, CEO of TruTechnologies. “Our new headquarters at Park Point gives us room to grow, sharper alignment with our life-science community, and a place that reflects the energy and precision we bring to our work – helping sponsors know what’s happening, when it happens.”

TruTechnologies enables sponsor organizations to gain visibility into site activity, data collection, and clinical trial execution – delivering faster access to cleaner data, stronger site-sponsor collaboration, and greater confidence in trial oversight. The relocation underscores the company’s ongoing investment in its people, operations, and technology, allowing it to serve a growing roster of global pharmaceutical and biotechnology partners while staying closely connected to the research institutions and innovation networks that define RTP.

About TruTechnologies
Founded in 2018, TruTechnologies is the leading provider of real-time clinical trial oversight, focused on enabling timely, high-quality data and mitigating risks in drug development. The company partners with six top 20 pharmaceutical companies and numerous biotechnology firms to accelerate patient screening and enrollment, drive protocol adherence, and correct deviations.

Media Contact
Sarah Sinning
Sr. Marketing Associate
sarah.sinning@tru.team